Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MDXG 
MiMedx Group Inc (MDXG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: MDXG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $12
1 Year Target Price $12
| 5 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 19.34% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 877.35M USD | Price to earnings Ratio 22 | 1Y Target Price 12 |
Price to earnings Ratio 22 | 1Y Target Price 12 | ||
Volume (30-day avg) 5 | Beta 1.8 | 52 Weeks Range 5.47 - 10.14 | Updated Date 06/30/2025 |
52 Weeks Range 5.47 - 10.14 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.27 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 11.4% | Operating Margin (TTM) 9.35% |
Management Effectiveness
Return on Assets (TTM) 13.8% | Return on Equity (TTM) 22.29% |
Valuation
Trailing PE 22 | Forward PE 19.53 | Enterprise Value 789577711 | Price to Sales(TTM) 2.49 |
Enterprise Value 789577711 | Price to Sales(TTM) 2.49 | ||
Enterprise Value to Revenue 2.24 | Enterprise Value to EBITDA 12.71 | Shares Outstanding 147702000 | Shares Floating 109326170 |
Shares Outstanding 147702000 | Shares Floating 109326170 | ||
Percent Insiders 1.71 | Percent Institutions 70.13 |
Analyst Ratings
Rating 3 | Target Price 12 | Buy - | Strong Buy 5 |
Buy - | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
MiMedx Group Inc
Company Overview
History and Background
MiMedx Group, Inc. was founded in 2008. Initially focused on amniotic tissue products for wound care, it faced accounting scandals in 2018 and underwent significant restructuring. It has since refocused on regenerative medicine.
Core Business Areas
- Wound Care: Focuses on advanced wound care products derived from placental tissues, including products for chronic and acute wounds.
- Surgical and Sports Medicine: Offers products for surgical applications and sports medicine, aiming to improve tissue repair and reduce recovery time.
Leadership and Structure
The leadership team includes Joseph H. Capper (Chairman & CEO), and Pete Petit (Former CEO, no longer with the company). The organizational structure is typical of a publicly traded company, with departments focused on sales, marketing, R&D, manufacturing, and finance.
Top Products and Market Share
Key Offerings
- EpiFix: A dehydrated human amnion/chorion membrane (dHACM) allograft used in wound care. While specific market share data is difficult to ascertain precisely, it's considered a leading product in its category. Competitors include Organogenesis, Integra LifeSciences, and Smith & Nephew.
- AmnioFix: A dHACM allograft used in surgical and sports medicine applications. Similar to EpiFix, specific market share is hard to come by, but it is a key product. Competitors are similar to those for EpiFix, along with Stryker and DePuy Synthes.
Market Dynamics
Industry Overview
The regenerative medicine and advanced wound care industries are experiencing growth driven by an aging population, increasing prevalence of chronic diseases (like diabetes), and advancements in tissue engineering.
Positioning
MiMedx is positioned as a leader in placental tissue-based products for wound care and surgical applications. Its competitive advantage lies in its proprietary processing techniques and extensive clinical data supporting its products.
Total Addressable Market (TAM)
The TAM for wound care and regenerative medicine is estimated to be billions of dollars. MiMedx is well-positioned to capture a significant portion of this market.
Upturn SWOT Analysis
Strengths
- Proprietary technology
- Extensive clinical data
- Established sales force
- Strong brand recognition within its niche
Weaknesses
- Past accounting scandals damage to reputation
- Reliance on a limited product portfolio
- Regulatory scrutiny
- Potential fluctuations in reimbursement rates
Opportunities
- Expanding into new therapeutic areas
- Strategic partnerships and acquisitions
- Increasing international presence
- Developing new products using placental tissue
Threats
- Increased competition
- Changes in reimbursement policies
- Potential product liability claims
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- ORG
- INTE
- SNY
Competitive Landscape
MiMedx faces competition from larger, more diversified medical technology companies. Its advantage lies in its focus on placental tissue products and its established presence in the wound care market. Disadvantages include its smaller size and past controversies.
Major Acquisitions
Stability Biologics
- Year: 2023
- Acquisition Price (USD millions): 18
- Strategic Rationale: The acquisition added amniotic fluid-derived allograft technology to MiMedx's portfolio.
Growth Trajectory and Initiatives
Historical Growth: MiMedx's historical growth was significantly impacted by its accounting scandal. Recent years have focused on rebuilding trust and stabilizing operations.
Future Projections: Analyst estimates for future growth vary. Consensus estimates typically project revenue growth in the coming years, driven by increased adoption of its products.
Recent Initiatives: Recent initiatives include new product launches, expansion of its sales force, and efforts to strengthen its relationships with healthcare providers.
Summary
MiMedx has overcome past challenges and is now focused on growth within the regenerative medicine field, particularly wound care. The company possesses innovative technology in placental tissue products, yet it faces competition and needs to expand its product portfolio. Recent acquisition of Stability Biologics shows promise for expanding revenue generation. Continued focus on compliance, innovation, and sales execution will be key for its future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. The data provided is based on publicly available information and may not be entirely accurate or complete. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MiMedx Group Inc
Exchange NASDAQ | Headquaters Marietta, GA, United States | ||
IPO Launch date 2007-08-22 | CEO & Director Mr. Joseph H. Capper | ||
Sector Healthcare | Industry Biotechnology | Full time employees 837 | Website https://www.mimedx.com |
Full time employees 837 | Website https://www.mimedx.com | ||
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.